Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 16/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24186661 | 0.87 | GLP1R (0.66) | GLP1R | |
| SCHEMBL23980905 | 0.84 | GLP1R (0.56) | GLP1RDRD2GRM2DRD3 | |
| SCHEMBL23980798 | 0.83 | GLP1R (0.51) | GLP1RDRD2GRM2DRD3 | |
| SCHEMBL26024848 | 0.82 | GLP1R (0.66) | GLP1R | |
| SCHEMBL25815319 | 0.81 | GLP1R (0.52) | GLP1RDRD2GRM2 | |
| SCHEMBL25815330 | 0.81 | GLP1R (0.52) | GLP1RDRD2GRM2 | |
| SCHEMBL25816019 | 0.80 | GLP1R (0.58) | GLP1R | |
| SCHEMBL26518481 | 0.80 | GLP1R (0.58) | GLP1R | |
| SCHEMBL25700951 | 0.79 | GLP1R (0.57) | GLP1RDRD2GRM2DRD3 | |
| SCHEMBL25815635 | 0.79 | GLP1R (0.64) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885DRD2 2267/4885GRM2 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.